FDA Increases Scrutiny on Skincare Marketing Claims
The FDA is cracking down on misleading claims in the skincare industry, with a focus on anti-aging and sun protection products. This heightened regulatory enforcement could lead to product recalls or reformulations by brands. Such actions often create opportunities for off-price retailers to acquire discontinued inventory.
- The most significant update to the FDA's oversight is the Modernization of Cosmetics Regulation Act of 2022 (MoCRA), the first major amendment to cosmetics law since 1938. This act grants the FDA new authorities, including mandatory recall power, which it previously lacked. - The FDA distinguishes between cosmetics and drugs based on their intended use; claims that a product can affect the structure or function of the body, such as "enhancing collagen production" or "repairing skin," can classify a product as a drug, subjecting it to stricter regulation. - In August 2025, the FDA issued warning letters to brands like Supergoop! and Vacation Inc. for marketing sunscreen in unapproved mousse and foam formats, deeming the products unlawful to market without a new drug application. - Beyond marketing claims, product recalls are also driven by contamination. In March 2025, brands including La Roche-Posay and Proactiv voluntarily recalled specific acne products after FDA testing revealed elevated levels of benzene, a known carcinogen. - The financial impact of a significant product recall can be substantial, with one 2017 analysis finding the average cost for companies to be around $12 million, covering expenses like product replacement and business interruption. - This type of regulatory action is not new, but enforcement is increasing; in 2012, the FDA issued similar warning letters to major brands like Avon and Lancôme for making anti-aging claims that positioned their products as unapproved drugs. - The FDA also issues warning letters for adulterated products due to microbial contamination, such as *Pseudomonas aeruginosa*, which can pose health risks and lead to recalls. - TJX's business model is structured to capitalize on these situations, with over 1,300 buyers sourcing inventory from a network of more than 21,000 vendors, often acquiring merchandise from manufacturing overruns or discontinued lines at 20% to 60% below original prices.
